Pda Technical Report 82 ((exclusive)) Site

The PDA first published Technical Report 82 in 2015, with the aim of providing a detailed framework for evaluating sterile compounding facilities. The report was developed by a team of experts with extensive experience in sterile compounding, facility design, and regulatory compliance. TR 82 provides guidance on the key elements of sterile compounding facilities, including design, construction, and operation.

By establishing industry-wide consensus, TR 82 helps manufacturers align with global regulatory expectations from the FDA and EMA. Key Requirements for LER Hold Studies pda technical report 82

Demasking involves adding specific reagents to break down the surfactant-chelator complex, thereby liberating the endotoxin so it can react with the LAL enzyme. Common demasking agents include: Bovine Serum Albumin (BSA) to bind surfactants. Divalent cations (e.g., Mg2+cap M g raised to the 2 plus power Ca2+cap C a raised to the 2 plus power ) to neutralize chelators. Specific diluents that alter the sample matrix physics. Alternative Endotoxin Detection Methods The PDA first published Technical Report 82 in